Skip to main content

Table 8 Summary of measured amyloid-β 1–42 peptide concentrations for samples from study I4O-MC-BACA (n = 48) using both Quanterix and Fujirebio amyloid-β 1–42 peptides for calibration

From: A digital enzyme-linked immunosorbent assay for ultrasensitive measurement of amyloid-β 1–42 peptide in human plasma with utility for studies of Alzheimer’s disease therapeutics

 

1–42 (pg/ml)

Quanterix Aβ1–42 peptide calibration

Fujirebio Aβ1–42 peptide calibration

Subject

Dose

0 h

1 h

6 h

12 h

0 h

1 h

6 h

12 h

A

Placebo

16.8

16.9

17.0

18.1

39.7

39.9

40.0

42.9

D

Placebo

14.7

13.3

10.9

12.0

34.4

31.1

25.1

27.8

G

Placebo

18.6

18.8

18.3

20.8

43.9

44.6

43.3

49.4

B

7 mg

18.7

12.2

8.03

8.25

44.3

28.3

17.9

18.5

C

7 mg

21.0

19.6

7.64

6.70

49.9

46.4

17.0

14.6

E

7 mg

20.4

22.8

9.48

12.0

48.4

54.2

21.5

27.9

A

15 mg

16.9

13.1

5.65

6.61

39.8

30.6

11.9

14.3

F

15 mg

17.4

14.4

5.99

5.74

41.1

33.7

12.8

12.1

K

15 mg

20.5

14.2

6.51

5.95

48.8

33.3

14.1

12.7

H

35 mg

21.7

16.8

4.80

4.88

51.5

39.7

9.74

9.94

I

35 mg

18.6

15.5

7.43

5.27

44.1

36.4

16.4

11.0

J

35 mg

19.5

19.1

6.92

4.56

46.3

45.2

15.1

9.12

  1. amyloid-β